ACRS ▼ -6.0% - Aclaris Therapeutics, Inc.
$ACRS - Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
16-NOV-2026 03:28 AM ET
Share this post
More filings for $ACRS
ACRS ▼ -6.0% - Aclaris Therapeutics, Inc.Nov 16, 2026ACRS ▲ +1.8% - Aclaris Therapeutics, Inc.Nov 12, 2026ACRS ▲ +3.8% - Aclaris Therapeutics, Inc.Nov 5, 2026ACRS ▼ -3.4% - Aclaris Therapeutics, Inc.Oct 27, 2026ACRS ▼ -4.0% - Aclaris Therapeutics, Inc.Oct 27, 2026ACRS - Aclaris Therapeutics, Inc. - SEC Filing Update (21-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 21, 2026
View full $ACRS filing history →💬 Comments
Loading comments…
Leave a comment
